Consensus AB Science

Equities

AB

FR0010557264

Market Closed - Euronext Paris Other stock markets 16:35:15 26/04/2024 BST			5-day change	1st Jan Change
1.936 ^EUR	+2.76%		-1.63%	-45.54%

04-04	AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	MT
04-03	AB Science: reconsideration possible for masitinib in ALS	CF

Evolution of the average Target Price on AB Science

Price target over the last 5 years

History of analyst recommendation changes

3f3b00f61030bd9dd01d76e3.t370_4oa2JbIKaqzVkSMQ9oy6D60qm8uf4QDgvaNhNg.2zC8t95Z6-CYe9vSHx3IBpZ6vlj6wD1rRsEx56_JyfX5JrK0626X954d-w~c14f4da128cb26f57f94ab4d27131e72

Analyst Recommendations on AB Science

AB Science : Masitinib Treatment Against Pancreatic Cancer Boosts Survival Rates	04/12/20	MT
SCIENCE : AB Science: Chardan Capital Markets initiates coverage with a BUY recommendation on AB Science and a target price of €30	05/05/15	GL

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.936 EUR

Average target price

6.895 EUR

Spread / Average Target

+256.15%

High Price Target

10 EUR

Spread / Highest target

+416.53%

Low Price Target

3.79 EUR

Spread / Lowest Target

+95.76%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar